

Regimen Monograph

[Regimen Name](#) | [Drug Regimen](#) | [Cycle Frequency](#) | [Premedication and Supportive Measures](#) | [Dose Modifications](#) | [Adverse Effects](#) | [Interactions](#) | [Drug Administration and Special Precautions](#) | [Recommended Clinical Monitoring](#) | [Administrative Information](#) | [References](#) | [Other Notes](#) | [Disclaimer](#)

A - Regimen Name

ECARBOX Regimen

Epirubicin-Carboplatin-Capecitabine (XELODA)®

Disease Site Gastrointestinal
 Esophagus
 Gastric / Stomach

Intent Palliative

Regimen Category **Evidence-Informed :**

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

Rationale and Uses An alternative to ECF for treatment of advanced (non-resectable; either locally advanced or metastatic) gastric, esophageal or gastroesophageal cancer, but not for squamous cell carcinomas.

Supplementary Public Funding [capecitabine](#)
ODB - General Benefit (capecitabine)

[back to top](#)

B - Drug Regimen

EPIrubicin	50 mg /m ²	IV	Day 1
CARBOplatin	AUC 5	IV	Day 1
capecitabine	625 mg /m ²	PO	BID* days 1 to 21

(*Total daily dose = 1250mg/m²/day; outpatient prescription in 150mg and 500mg tablets)

[back to top](#)

C - Cycle Frequency**REPEAT EVERY 21 DAYS**

For a maximum of up to 8 cycles unless disease progression or unacceptable toxicity occurs

[back to top](#)

D - Premedication and Supportive Measures

Antiemetic Regimen: Moderate + NK1 antagonist (Carboplatin AUC ≥ 5)
No routine prophylaxis for capecitabine

Febrile Neutropenia Risk: Low

Other Supportive Care:

- Topical emollients (e.g. hand creams, udder balm) may ameliorate the manifestations of hand-foot syndrome in patients receiving capecitabine.
- Supportive care should be provided, including loperamide for diarrhea.
- Also refer to [CCO Antiemetic Recommendations](#).

[back to top](#)

E - Dose Modifications

Doses should be modified according to the protocol by which the patient is being treated.

Patients should be tested for DPD deficiency before starting treatment with capecitabine. Refer to the [DPD Deficiency Guidance for Clinicians](#) for more information.

In patients with unrecognized DPD deficiency, acute, life-threatening toxicity may occur; if acute grade 2-4 toxicity develops, treatment should be stopped immediately and permanent discontinuation considered based on clinical assessment of the toxicities.

Dosage with toxicity

Worst Toxicity Grade/ Counts (x 10 ⁹ /L) in Prior Cycle	Epirubicin (% previous dose)	Carboplatin Dose (% previous dose)	Capecitabine
Febrile Neutropenia Thrombocytopenic bleeding Grade 4 ANC ≥ 7 d	Hold, then ↓ 75%*	Hold, then ↓ 1 AUC*/#	Refer to table below.
Cardiotoxicity**	Discontinue	No change	
Grade 3 related non- hematologic/organ	Hold, then ↓ 75%* for suspect drug	Hold, then ↓ 1 AUC* for suspect drug	
Grade 4 related non- hematologic/organ	Discontinue		

- * Do not retreat until toxicity has recovered to ≤ grade 2, and platelets ≥ 100 x 10⁹/L, and ANC ≥ 1.5 x 100⁹/L.
- **including any signs and symptoms of heart failure, greater than 10% decline in LVEF to below the lower limit of normal, a greater than 20% decline in LVEF from any level, or LVEF ≤ 45%.
- # Use Egorin formula if isolated thrombocytopenia (See Appendix section).

Capecitabine: Dose Modification:

Do not start treatment with capecitabine unless baseline neutrophil counts are ≥ 1.5 x 10⁹/L and/or platelet counts of ≥ 100 x 10⁹/L. Patients should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs. Supportive care should be provided, including loperamide for diarrhea. Doses should not be re-escalated if reduced for toxicity. Missed or omitted doses of capecitabine should not be replaced.

Dose modifications are mandatory for gastrointestinal, dermatological toxicity and hyperbilirubinemia. Practitioner may elect not to reduce dose for other toxicities unlikely to become serious or life-threatening.

Toxicity	Action During a Course of Therapy	Dose Adjustment for Next Cycle (% of starting dose)
Grade 1	Maintain dose level	Maintain dose level
Grade 2 1st appearance 2nd appearance 3rd appearance 4th appearance	Interrupt until resolved to grade 0-1 Interrupt until resolved to grade 0-1 Interrupt until resolved to grade 0-1 Discontinue treatment permanently	100% 75% 50% –
Grade 3 1st appearance 2nd appearance 3rd appearance, OR any evidence of Stevens-Johnson syndrome or Toxic epidermal necrolysis	Interrupt until resolved to grade 0-1 Interrupt until resolved to grade 0-1 Discontinue treatment permanently	75% 50% –
Grade 4 1st appearance, including SJS or TEN, OR cardiotoxicity OR acute renal failure 2nd appearance	Discontinue permanently OR If physician deems it to be in the patient's best interest to continue and no evidence of Stevens-Johnson syndrome or toxic epidermal necrolysis, interrupt until resolved to grade 0-1. Discontinue permanently	Discontinue OR 50% Not applicable

Hepatic Impairment

Epirubicin is contraindicated in patients with severe hepatic impairment, especially with elevated bilirubin. Consideration should be given to dose modification for patients with severe increases in transaminases.

Capecitabine: In patients with mild to moderate hepatic impairment, exposure is increased but no dose adjustment is necessary, although caution should be exercised. Use dose modification table above for increases in bilirubin. The use of capecitabine in patients with severe hepatic impairment has not been studied.

Bilirubin (μmol/L)		AST/ALT	Epirubicin (% usual dose)	Carboplatin	Capecitabine
1-2 x ULN	or	2-4 x ULN	50%	No change	Use capecitabine dose modification table above
2-4 x ULN	or	> 4 x ULN	25%		
> 4 x ULN		omit	Omit		

Renal Impairment

Creatinine Clearance (ml/min)	Epirubicin (% previous dose)	Carboplatin (% previous dose)	Capecitabine (% previous dose)
51 - 80	No change	No change	100 % with close monitoring
30 - 50		Use Calvert or Chatelut formula	75% (use with caution)
21 - 29			CONTRAINDICATED
< 20	Adjust dose with severe renal impairment (creatinine > 440 μmol/L)	Discontinue	

[back to top](#)

F - Adverse Effects

Refer to [EPIrubicin](#), [CARBOplatin](#), [capecitabine](#) drug monograph(s) for additional details of adverse effects

Most common adverse effects	Less common adverse effects, but may be severe or life-threatening
<ul style="list-style-type: none">• Alopecia• Hand-foot syndrome (may be severe)• Mucositis• Diarrhea (may be severe), abdominal pain• Nausea, vomiting• Myelosuppression +/- bleeding, infection• Fatigue• ↑ LFTs (may be severe)• Ototoxicity• Nephrotoxicity• Electrolyte abnormalities	<ul style="list-style-type: none">• Cardiotoxicity• Hypersensitivity• Arterial thromboembolism• Venous thromboembolism• Rash• Radiation recall reaction• Neuropathy• GI obstruction, perforation• Hemolytic uremic syndrome, ITP• Pneumonitis• Secondary malignancy

[back to top](#)

G - Interactions

Refer to [EPIrubicin](#), [CARBOplatin](#), [capecitabine](#) drug monograph(s) for additional details

[back to top](#)

H - Drug Administration and Special Precautions

Refer to [EPIrubicin](#), [CARBOplatin](#), [capecitabine](#) drug monograph(s) for additional details

[back to top](#)

I - Recommended Clinical Monitoring

Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.

Recommended Clinical Monitoring

- CBC; baseline and before each cycle
- Liver function tests; baseline and regular
- Renal function tests; baseline and regular including electrolytes
- Cardiac function tests (Echo, RNA and/or MUGA scans) for all patients with cardiac risk factors or cumulative epirubicin doses > 650mg/m²; baseline and periodic
- INR and/or PT; Baseline and regular if on anticoagulants
- Clinical toxicity assessment for neurotoxicity, ototoxicity, hypersensitivity, bleeding, infection, GI, cardiac and skin effects; at each visit
- Grade toxicity using the current [NCI-CTCAE \(Common Terminology Criteria for Adverse Events\) version](#)

[back to top](#)

J - Administrative Information

Approximate Patient Visit	1 hour
Pharmacy Workload (average time per visit)	27.365 minutes
Nursing Workload (average time per visit)	65.833 minutes

[back to top](#)

K - References

Capecitabine, epirubicin, carboplatin drug monographs, Cancer Care Ontario.

Cunningham D , Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008 Jan 3;358(1):36 - 46.

Cunningham D, Allum WH, Stenning SP, et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med 2006; 355: 11-20.

PEBC Advice Documents or Guidelines

- [Systemic Therapy for Advanced Gastric and Gastro-Esophageal Carcinoma](#)

April 2023 Updated DPD deficiency information in the Dose Modifications section

[back to top](#)

L - Other Notes

Calvert Formula

DOSE (mg) = target AUC X (GFR + 25)

- AUC = product of serum concentration (mg/mL) and time (min)
- GFR (glomerular filtration rate) expressed as measured Creatinine Clearance or estimated from Serum Creatinine (by Cockcroft and Gault method or Jelliffe method)

(Calvert AH, Newell DR, Gumbrell LA, et al, Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol, 1989; 7: 1748-1756)

Egorin Formula

Previously Untreated Patients-

$$\text{DOSE (mg/m}^2\text{)} = 317 \left[\left\{ \left[\frac{(\text{pre} - \text{nadir})}{\text{pre}} \right] 100 - 82.1 \right\} \times (\text{BSA} / \text{Cr Cl}) \right] + 447$$

Previously Treated Patients-

$$\text{DOSE (mg/m}^2\text{)} = 317 \left[\left\{ \left[\frac{(\text{pre} - \text{nadir})}{\text{pre}} \right] 100 - 92.4 \right\} \times (\text{BSA} / \text{Cr Cl}) \right] + 447$$

- Pre = pretreatment platelet count
- Nadir = platelet nadir desired
- BSA = Body Surface Area
- Cr Cl = Creatinine Clearance

(Egorin MJ, Van Echo DA, Tipping SJ, et al, Pharmacokinetics and dosage reduction of carboplatin in patients with impaired renal function. Cancer Res, 1984; 44: 5432-5438)

[back to top](#)

M - Disclaimer

Regimen Abstracts

A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis,

without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.

Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Regimen Monographs

Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary's content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

[back to top](#)